Drug Profile
Research programme: glioblastoma therapeutic - Parabon Nanolabs
Alternative Names: P24RDNLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Parabon NanoLabs
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in USA
- 07 Dec 2012 Preclinical trials in Glioblastoma in USA (unspecified route)